# PYRIMIDOISOQUINOLINE DERIVATIVES

## Claims
Pyrimidoisochinolin Derivate der Formel

## Description
This invention relates to new pyrimidoisoquinoline derivatives. More particularly, it relates to new pyrimidoisoquinoline derivatives and pharmaceutically acceptable salts thereof, to processes for the preparation of the pyrimidoisoquinoline derivatives and to pharmaceutical compositions comprising these compounds. The pyrimidoisoquinoline derivatives of this invention have anti allergic activities and are useful in the treatment of symptoms associated with allergic manifestations such as, for example, asthmatic conditions. US A 4, 127,720 describes various pyrimidoisoquinoline derivatives which exhibit anti allergic activity when administered either orally or parenterally. Pyrimidoisoquinoline derivatives of this invention can be represented by the following formula wherein R¹ is C₁ C₄ alkyl, The pharmaceutically acceptable salts of the pyrimidoisoquinoline derivatives I may include a salt with an inorganic or organic base e.g. sodium salt, potassium salt, ethanolamine salt, or tris hydroxymethyl methylammonium salt and an acid addition salt e.g. hydrochloride . According to this invention, the new pyrimidoisoquinoline derivatives I and pharmaceutically acceptable salts thereof can be prepared by, for example, the following processes. wherein The starting compound II or a salt thereof is a new compound and can be prepared by, for example, the preparation as illustrated below and in a similar manner thereto. In the above and subsequent descriptions of this specification, suitable examples and illustrations of the various definitions are explained in detail in the following. The term lower is intended to mean 1 to 6 carbon atom s , unless otherwise indicated. The term higher is intended to mean more than 6 carbon atoms, and more preferably 7 to 20 carbon atoms. Suitable C₁ C₄ alkyl may include methyl, ethyl, propyl, isopropyl, butyl, isobutyl and t butyl. Suitable C₁ C₆ alkanoyl include formyl, acetyl, propionyl, butyryl, isobutyryl, 3,3 dimethylbutyryl, valeryl, isovaleryl and pivaloyl. Suitable C₇ C₂₀ alkanoyl include heptanoyl, 2,3 dimethylpentanoyl, lauroyl, myristoyl, palmitoyl and stearoyl. Suitable C₄ C₈ cycloalkyl carbonyl include cyclopentylcarbonyl, cyclohexylcarbonyl and cycloheptylcarbonyl. Suitable C₁ C₆ alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl. Suitable C₁ C₆ alkanesulfonyl include mesyl, ethanesulfonyl and propanesulfonyl. Suitable C₁ C₆ alkoxycarbonyl , which may contain heterocyclic carboxamido e.g. nicotinamido , include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, t butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl and 2 nicotinamidoethoxycarbonyl. Suitable alkoxy may include alkoxy groups such as propoxy, isopropoxy, butoxy, isobutoxy, t butoxy, pentyloxy and hexyloxy. The processes as illustrated above are explained in more detail in the following. The object compound Ia or a salt thereof can be prepared by reacting the compound II or a salt thereof with the compound III . The salt of the compound II is an acid addition salt e.g. hydrochloride or sulfate . This reaction is usually carried out in a solvent which does not adversely influence the reaction such as N,N dimethylformamide, propanol, isobutyl alcohol, diphenylether, toluene or xylene under heating. The compound Ic or a salt thereof can be prepared by reducing the compound Ib or a salt thereof. The reduction is carried out in a conventional manner such as a reduction using a reducing agent e.g. combination of iron and ammonium chloride, etc. , catalytic reduction and the like. The reduction is usually carried out in a solvent which does not adversely influence the reaction such as water, ethanol, propanol, isobutyl alcohol, N,N dimethylformamide, tetrahydrofuran, chloroform and the like, at a temperature range of cooling to heating. The compound Id or a salt thereof can be prepared by reacting the compound Ic or its reactive derivative at the amino group or a salt thereof with an acylating agent. Suitable reactive derivative at the amino group of the compound Ic may include Schiff s base type imino or its tautomeric enamine type isomer formed by the reaction of the compound Ic with a carbonyl compound such as aldehyde, ketone or the like a silyl derivative formed by the reaction of the compound Ic with a silyl compound such as bis trimethylsilyl acetamide, trimethylsilylacetamide or the like a derivative formed by reaction of the compound Ic with phosphorus trichloride or phosgene, and the like. The acylating agent to be used in this reaction includes an organic acid i.e. R 2 b OH IV , in which R 2 b is acyl and its reactive derivative. The suitable reactive derivative of the compound IV may be a conventional ones such as an acid halide e.g. acid chloride, acid bromide, etc. , an acid azide an acid anhydride, an activated amide, an activated ester, an isocyanate and the like. When free acid is used as an acylating agent, the acylation reaction may preferably be conducted in the presence of a conventional condensing agent. The reaction is usually conducted in a solvent which does not adversely influence the reaction such as N,N dimethylformamide, dimethylsulfoxide, tetrahydrofuran, dichloromethane, chloroform, pyridine or a mixture thereof. The reaction can also be conducted preferably in the presence of an organic or inorganic base such as alkali metal e.g. sodium , alkaline earth metal e.g. calcium , alkali or alkaline earth metal hydride e.g. sodium hydride, calcium hydride, etc. , alkali or alkaline earth metal hydroxide e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide, etc. , alkali or alkaline earth metal carbonate or bicarbonate e.g. sodium carbonate, potassium carbonate, sodium bicarbonate , alkali or alkaline earth metal alkoxide e.g. sodium ethoxide, lithium methoxide, magnesium methoxide , trialkylamine e.g. triethylamine , pyridine, bicyclodiaza compound e.g. 1,5 diazabicyclo 3,4,0 nonene 5, 1,5 diazabicyclo 5,4,0 undecene 5, etc. and the like. The reaction may preferably be conducted within the range of cooling to ambient temperature. The compound Ie or a salt thereof can be prepared by subjecting the compound Ia or a salt thereof to removal reaction of the carboxy protective group. The removal reaction of this process may include hydrolysis, reduction and the like. The hydrolysis is preferably carried out in the presence of inorganic or organic acid e.g. hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, etc. , or inorganic or organic base e.g. sodium hydroxide, etc. . The reaction of this process is usually carried out in a solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, acetic acid and the like, at a temperature range of cooling to heating. When the starting compound Ia has acylamino substituted by acyloxy for R², acyl group of said acyloxy may occasionally be removed off to transform into hydrogen together with removal of carboxy protective group in this reaction. This case is also included within the scope of this invention. The compound If or a salt thereof can be prepared by reacting the compound Ie or its reactive derivative at the carboxy group or a salt thereof with an amidating agent. The amidating agent may include an amine i.e. R 3 e NH₂ V , in which R 3 e is a suitable substituent s such as heterocyclic group, ar lower alkyl heterocyclic lower alkyl and its reactive derivative or a salt thereof. Suitable reactive derivative of the compound Ie may include an acid halide, an acid anhydride, an activated ester and the like. Suitable reactive derivative of the compound V may be the same one as that of the compound Ic . This reaction is usually carried out in a solvent which does not adversely influence the reaction such as N,N dimethylformamide, dimethylsulfoxide, pyridine, dichloromethane and the like. The reaction temperature is not critical, and the reaction be carried out within the temperature range of cooling to heating. This reaction is preferably carried out in the presence of a condensing agent e.g. 1,1 carbonyldiimidazole, etc. . The compound Ig or a salt thereof can be prepared by reacting the compound Ie or its reactive derivative at the carboxy group or a salt thereof with an esterifying agent. The esterifying agent may include an alcohol i.e. R 3 f OH VI , in which R 3 f is a suitable substituent s such as lower alkyl which may have heterocyclic carboxamido and its reactive derivative or a salt thereof. Suitable reactive derivative of the compound Ie may include an acid halide, an acid anhydride, an activated ester and the like. Suitable reactive derivative of the compound VI may include the corresponding halide e.g. alkyl halide , diazocompound e.g. diazoalkane , sulfonate alkylsulfonate , sulfate or salt with an alkali metal or alkaline earth metal and the like. This reaction is usually carried out in a solvent which does not adversely influence the reaction such as N,N dimethylformamide, dimethylsulfoxide, pyridine, dichloromethane and the like. The reaction temperature is not critical, and the reaction may be carried out within the temperature range of cooling to heating. The object compounds of the above processes 1 6 can be purified and converted to the desired salt in a conventional manner. The object compound I of this invention and pharmaceutically acceptable salt thereof possess strong antiallergic activity. Accordingly, the object compound of this invention is useful for the treatment of symptoms associated with allergic diseases such as allergic asthma, allergic rhinitis, urticaria, pollenosis allergic conjunctivitis, atopic dermatitis, ulcerative colitis, alimentary allergy e.g. milk allergy , bird fancier s disease, aphthous stomatitis and the like. For illustrating purpose, the antiallergic activity of some representative compounds of the object compound I are shown in the following. Test results are shown in the following table. The pyrimidoisoquinoline derivatives I of this invention can be used as an active antiallergic agent either in free form or in the form of the pharmaceutically acceptable salt such an a salt with inorganic or organic acid, a salt with inorganic or organic base and a salt with an amino acid. The object compound I or its pharmaceutically acceptable salt can usually be administered to mammals including human beings in the form of a conventional pharmaceutical composition such as capsule, micro capsule, tablet, granule, powder, troche, syrup, aerosol, inhalation, solution, injection, suspension, emulsion, suppository, ointment, or the like. The pharmaceutical composition of this invention can contain various organic or inorganic carrier materials, which are conventionally used for pharmaceutical purpose, such as excipient e.g. sucrose, starch, mannit, sorbit, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate, etc. , binding agent cellulose, methyl cellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose, starch, etc. , disintegrator e.g. starch, carboxymethyl cellulose, calcium salt of carboxymethyl cellulose, hydroxypropylstarch, sodium glycole starch, sodium bicarbonate, calcium phosphate, calcium citrate, etc. , lubricant e.g. magnesium stearate, talc, sodium laurylsulfate, etc. , flavoring agent e.g. citric acid, mentol, glycine, orange powders, etc. , preservative sodium benzoate, sodium bisulfite, methylparaben, propylparaben, etc. , stabilizer citric acid, sodium citrate, acetic acid, etc. , suspending agent e.g. methyl cellulose, polyvinylpyrrolidone, aluminum stearate, etc. , dispersing agent, aqueous diluting agent e.g. water , base wax e.g. cacao butter, polyethyleneglycol, white petrolatum, etc. . A dosage of the present active ingredient is to be varied depending on various factors such an weight and or age of a patient and or a stage of the allergic disease, and further the kind of administration route. In general, an effective dosage may be in a range of about 20 2000 mg day for an oral route, about 2.5 250 mg day for an intramuscular or intravenous injection, about 10 1000 mg day for a subcutaneous injection and about 120 mg 2000 mg day for a rectal route. The total daily amount mentioned above may be divisionally given to the patient at the interval of 6 12 hours per day. Preferable single dose of the present active ingredient may be, for example, about 10 500 mg per tablet or capsule, about 1.25 250 mg per vial or ampoule, or about 60 500 mg per suppository, and so on, and further a pharmaceutical form for an external use may be, for example, about 1 10 ointment, solution or emulsion, etc. Starting compounds to be used in the preparation of the pyrimidoisoquinoline derivatives I of this invention can be specifically prepared in the following manner. The following compound was obtained according to a similar procedure to that of Preparation 1 4 . The following compound was obtained according to a similar procedure to that of Preparation 1 4 . The following Examples are given for the purpose of illustrating this invention. A mixture of 1 amino 4 methyl 7 nitroisoquinoline 3.87 g , diethyl ethoxymethylenemalonate 4.53 g in N,N dimethylformamide 20 ml was heated at 120 C with stirring for 4 hours. Additional diethyl ethoxymethylene malonate 1 g was added to the mixture, and then the reaction mixture was refluxed for 18 hours and cooled to give precipitate. The crystals obtained were filtered off and washed with cold ethanol to give ethyl 7 methyl 10 nitro 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 4.21 g . A suspension of ethyl 7 methyl 10 nitro 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 260 mg in a mixture of acetic acid 6 ml and 36 hydrochloric acid 3 ml was refluxed for 50 minutes. The mixture was cooled to 0 C to give yellow solid. The yellow solid was collected and dried to give 7 methyl 10 nitro 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid 180 mg . To a stirred mixture of ethyl 7 methyl 10 nitro 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 140 mg and iron powder 90 mg in a mixture of water 0.5 ml and ethanol 13 ml was added a solution of ammonium chloride 90 mg in water 0.5 ml under refluxing. After refluxing for 1 hour and 50 minutes, ammonium chloride 28 mg in water 0.5 ml and iron 50 mg was added, and then the mixture was stirred for additional 1 hour. The reaction mixture was filtered and the residue on a filter was washed with hot ethanol. The filtrate was concentrated in vacuo and then treated with dilute sodium hydrogen carbonate solution to give crude product. Chromatography on silica gel with chloroform methanol gave pure ethyl 10 amino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 100 mg . A suspension of ethyl 10 amino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 400 mg in a mixture of acetic acid 6 ml and 36 hydrochloric acid 3 ml was refluxed for 55 minutes. The mixture was cooled and diluted with water. The precipitated solid obtained was collected and dissolved into 6 ml of 1N aqueous sodium hydroxide. The resulting solution was filtered for removal of insoluble materials. The filtrate obtained was cooled and adjusted to pH 6 with 1N hydrochloric acid and neutralized with acetic acid to give 10 amino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid 270 mg . To a solution of ethyl 10 amino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 1.5 g in pyridine 110 ml was added 2,3 dimethylpentanoyl chloride 1.49 g under ice cooling. After stirring for 2 hours at ambient temperature, the reaction mixture was concentrated in vacuo. The residue in chloroform 100 ml was washed with water, a cold 1N hydrochloric acid and water in turn and dried over magnesium sulfate. After removal of the solvent, the residue was chromatographed on a silica gel column using chloroform as an eluent to give ethyl 10 2,3 dimethylpentanoylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 1.94 g . A mixture of ethyl 10 2,3 dimethylpentanoylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 500 mg and 1N sodium hydroxide 3.6 ml in methanol 20 ml was stirred at ambient temperature for 40 hours. The following compound was obtained according to a similar procedure to that of Example 5. Ethyl 10 pivaloylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate. A mixture of ethyl 10 pivaloylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 400 mg and 1N sodium hydroxide 3.1 ml in aqueous methanol 19 ml was stirred at ambient temperature for 2 days. Aqueous methanol was added to the reaction mixture and then heated on a water bath until almost all the precipitate was dissolved. The solution was filtered, and the filtrate was acidified with 1N hydrochloric acid. The resultant precipitate was collected, washed successively with water and methanol, and dried. Recrystallization from a mixture of N,N dimethylformamide and water gave pure 10 pivaloylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid 0.31 g . The following compound was obtained according to a similar procedure to that of Example 5. Ethyl 10 cyclohexyl carbonylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate The following compound was obtained according to a similar manner to that of Example 5. Ethyl 10 isobutyrylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate To a stirred suspension of 10 2,3 dimethylpentanoylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid 257 mg in N,N dimethylformamide 3.5 ml was added 1,1 carbonyldiimidazole 142 mg at ambient temperature under an inert atmosphere and then heated at 100 C. To the mixture was added 5 amino 1H tetrazol 75 mg , heated for 1 hour at the same temperature, and cooled. The resultant precipitate was collected by filtration, washed successively with N,N dimethylformamide and methanol, and dried to give N 1H tetrazol 5 yl 10 2,3 dimethylpentanoylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxamide 0.16 g . The following compound was obtained according to a similar procedure to that of Example 8. 10 Isobutyrylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid. The following compound was obtained according to a similar procedure to that of Example 8. 10 Cyclohexyl carbonylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid. A solution of 7 methyl 10 nitro 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid 300 mg in N,N dimethylformamide 40 ml was added to an aqueous sodium bicarbonate solution 60 ml . After being stirred for 1 hour, the mixture was allowed to stand in a refrigerator and the resultant precipitate was collected by filtration. To the solid was added aqueous methanol, stirred at room temperature, and collected by suction to give sodium 7 methyl 10 nitro 4 oxo 4H pyrimido 2, 1 a isoquinoline 3 carboxylate 0.29 g . A mixture of ethyl 10 2,3 dimethylpentanoylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 520 mg and 1N aqueous sodium hydroxide 3.6 ml in aqueous methanol 25 ml was stirred at room temperature for 2 days. Methanol was added to the reaction mixture until nearly all the precipitate was dissolved. The solution was concentrated to a half volume under reduced pressure and then filtered. The filtrate was diluted with water and allowed to stand in a refrigerator. The resultant precipitate was collected, washed with water and dried to give sodium 10 2,3 dimethylpentanoylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 210 mg . To a solution of ethyl 10 amino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 800 mg in pyridine 60 ml was added mesyl chloride 0.28 ml at ice bath temperature. The reaction mixture was allowed to stir overnight at room temperature and then concentrated in vacuo. The residue was collected, washed successively with 0.1N hydrochloric acid and water and recrystallized from N,N dimethylformamide to give ethyl 10 mesylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 0.76 g . The following compound was obtained according to a similar procedure to that of Example 16. Ethyl 10 ethoxycarbonylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate. The following compound was obtained according to a similar procedure to that of Example 8. 10 Mesylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid. The following compound was obtained according to a similar procedure to that of Example 16. Ethyl 10 ethoxyalylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate. To a solution of ethyl 10 amino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 600 mg in pyridine 60 ml was added phenyl isocyanate 0.22 ml at ice bath temperature. The reaction mixture was allowed to stir overnight at room temperature. The precipitate was collected, washed with methanol and dried. Recrystallization from dimethyl sulfoxide gave ethyl 10 3 phenylureido 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 0.58 g . The following compound was obtained according to a similar procedure to that of Example 1. Ethyl 10 nitro 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate. The following compound was obtained according to a similar procedure to that of Example 3. Ethyl 10 amino 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate. The following compound was obtained according to a similar procedure to that of Example 5. Ethyl 10 2,3 dimethylpentanoylamino 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate. The following compound was obtained according to a similar procedure to that of Example 8. 10 2,3 Dimethylpentanoylamino 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid. The following compound was obtained according to a similar procedure to that of Example 5. Ethyl 10 2 acetoxypropionylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate The following compound was obtained according to a similar procedure to that of Example 6. 10 2 Hydroxypropionylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid from ethyl 10 2 acetoxypropionylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate The following compound was obtained according to a similar procedure to that of Example 5. Ethyl 10 3,3 dimethylbutyrylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate The following compound was obtained according to a similar procedure to that of Example 6. 10 3,3 Dimethylbutyrylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid To a stirred mixture containing 10 2,3 dimethylpentanoylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid 455 mg , triethylamine 0.174 ml and dry dichloromethane 70 ml was added slowly ethyl chloroformate 0.12 ml at 0 C under an inert atmosphere. After being stirred for 2 hours, a solution of 2 4 diphenylmethyl 1 piperazinyl ethylamine 359 mg in dry dichloromethane 10 ml was added dropwise to the reaction mixture at 5 C. After stirring was continued for 12 hours at room temperature, the mixture was concentrated under reduced pressure. The residue was subjected to a column chromatography on silica gel with chloroform methanol. The eluate was concentrated in vacuo to give residue, which was recrystallized from chloroform ether to give N 2 4 diphenylmethylpiperazin 1 yl ethyl 7 methyl 10 2,3 dimethylpentanoylamino 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 0.59 g . A mixture of 10 2,3 dimethylpentanoylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid 250 mg and thionyl chloride 4 ml was stirred at 10 C for 30 minutes. The reaction mixture was stirred for 1 hour at room temperature, and then evaporated to dryness in vacuo to give an acid chloride. A mixture of the acid chloride, pyridine 0.1 ml and dry dichloromethane 60 ml was cooled to 5 C. A solution of N 2 hydroxyethyl nicotinamide 108 mg in dry dichloromethane was added to the mixture. The reaction mixture was stirred at 5 C for 1 hour, and allowed to stand at room temperature overnight. The reaction mixture was diluted with chloroform methanol, and washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was subjected to a column chromatography on silica gel with chloroform methanol. The eluate was concentrated in vacuo to give residue, which was recrystallized from chloroform ether to give 2 nicotinamido ethyl 7 methyl 10 2,3 dimethylpentanoylamino 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 0.26 g . The following compound was obtained according to a similar procedure to that of Example 42. 2 Nicotinamido ethyl 10 2,3 dimethylpentanoylamino 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate The following compound was obtained according to a similar procedure to that of Example 42. 2 Nicotinamido ethyl 10 pivaloylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate To a mixture of N nicotinoyl β alanine 2g and triethylamine 1.6ml in N,N dimethylformamide 200ml was added ethyl chloroformate 1.1ml at ice bath temperature. After being stirred for 1 hour at room temperature, ethyl 10 amino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 3g was added, and then the mixture was heated at 60 C for 3 hours. The reaction mixture was allowed to stir overnight at room temperature and then concentrated in vacuo. The residue was collected, washed successively with water and methanol and recrystallized from N,N dimethylformamide to give ethyl 10 3 nicotinoylamino propionylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylate 3.50g . The following compound was obtained according to a similar procedure to that of Example 6. 10 3 nicotinoylamino propropionylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic acid 10 2,3 Dimethylpentanoylamino 7 methyl 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic The above ingredients are blended and granulated or grained, in a conventional manner, into granules or small granules. 10 2,3 Dimethylpentanoylamino 4 oxo 4H pyrimido 2,1 a isoquinoline 3 carboxylic The above ingredients are blended and filled in hard gelatin capsules, in a conventional manner, to give 10,000 capsules, each of which contain 10 mg of an active ingredient.